Cargando...

An emerging treatment option for glaucoma: Rho kinase inhibitors

Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in Phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoske...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wang, Sean K, Chang, Robert T
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4025933/
https://ncbi.nlm.nih.gov/pubmed/24872673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S41000
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!